SAN DIEGO, June 27, 2016 /PRNewswire/ -- Aethlon Medical, Inc.
(Nasdaq: AEMD), announced today that it has been added to the Russell Microcap® Index. The annual
reconstitution of Russell U.S. Indexes became effective with the opening of the U.S. markets for trading today.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic
inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes.
"Our inclusion in the Russell Microcap® Index further expands our public market stature since listing on Nasdaq
less than a year ago. As a result of this inclusion, we anticipate that the awareness of our immunotherapeutic technology to
combat infectious disease and cancer will increase among the institutional investor community," stated Aethlon chairman and CEO,
Jim Joyce.
Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies. Approximately $6
trillion in assets are benchmarked against the Russell US Indexes.
For more information on the Russell Microcap® Index and the Russell US Indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Aethlon Medical
Aethlon Medical (Nasdaq:AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and
cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease
targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology
captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure
that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical
study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to
diagnose and monitor life-threatening diseases. Additional information can be found online at www.AethlonMedical.com or you can connect with us
on Twitter, LinkedIn, Facebook and Google+.
About FTSE Russell
FTSE Russell is a global index leader and data provider that provides innovative benchmarking, analytics and data solutions
for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes
in more than 70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
$10 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset
owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry
standards in index design and governance, and embraces the IOSCO principles. FTSE Russell is also focused on index innovation and
client collaboration as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com.
Contacts:
Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc.
212-986-6667
smarg@braincomm.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-joins-russell-microcap-index-300290305.html
SOURCE Aethlon Medical, Inc.